MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.

Phase 4
Completed
Conditions
Pain
Spinal Cord Injury
Interventions
First Posted Date
2006-05-03
Last Posted Date
2020-10-14
Lead Sponsor
Craig Hospital
Target Recruit Count
19
Registration Number
NCT00320281
Locations
🇺🇸

Craig Hospital, Englewood, Colorado, United States

Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy

Phase 3
Completed
Conditions
Spastic Diplegic Cerebral Palsy
First Posted Date
2005-12-02
Last Posted Date
2009-02-05
Lead Sponsor
Shriners Hospitals for Children
Target Recruit Count
250
Registration Number
NCT00261131

Intra-articularInjection of Botulinum Toxin Type

Phase 2
Conditions
Arthritis
Pain
First Posted Date
2005-09-21
Last Posted Date
2005-09-21
Lead Sponsor
Minneapolis Veterans Affairs Medical Center
Target Recruit Count
40
Registration Number
NCT00211679
Locations
🇺🇸

Minneapolis VAMC, Minneapolis, Minnesota, United States

Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain

Phase 1
Completed
Conditions
Cervical Dystonia
Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)
First Posted Date
2005-09-15
Last Posted Date
2016-06-01
Lead Sponsor
Vanderbilt University
Target Recruit Count
20
Registration Number
NCT00178945
Locations
🇺🇸

Vanderbilt Department of Neurology, Nashville, Tennessee, United States

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Phase 2
Completed
Conditions
Postherpetic Neuralgia
First Posted Date
2005-09-15
Last Posted Date
2011-05-30
Lead Sponsor
Allergan
Target Recruit Count
117
Registration Number
NCT00168441

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Phase 3
Completed
Conditions
Hyperhidrosis
First Posted Date
2005-09-15
Last Posted Date
2011-05-30
Lead Sponsor
Allergan
Target Recruit Count
193
Registration Number
NCT00168402

Vanderbilt University Spasticity Management Program Evaluation Plan

Phase 4
Completed
Conditions
Spasticity
First Posted Date
2005-09-15
Last Posted Date
2007-08-20
Lead Sponsor
Vanderbilt University
Target Recruit Count
20
Registration Number
NCT00179114
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Botulinum Toxin (BOTOX) for Cerebral Palsy

Phase 2
Completed
Conditions
Cerebral Palsy
Muscle Spasticity
First Posted Date
2003-05-19
Last Posted Date
2016-09-26
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Target Recruit Count
40
Registration Number
NCT00060957
Locations
🇺🇸

Children's Hospital and Regional Medical Center, Seattle, Washington, United States

Study of Botulinum Toxin in Patients With Primary Hyperhidrosis

Not Applicable
Completed
Conditions
Hyperhidrosis
First Posted Date
1999-10-19
Last Posted Date
2005-06-24
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Registration Number
NCT00004480
Locations
🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

Randomized Study of Botulinum Toxin Type A for Achalasia

Not Applicable
Completed
Conditions
Esophageal Achalasia
First Posted Date
1999-10-19
Last Posted Date
2015-03-25
Lead Sponsor
University of Texas
Target Recruit Count
56
Registration Number
NCT00004416
© Copyright 2025. All Rights Reserved by MedPath